In 2027, it is anticipated that the market for NGS sample preparation would grow to $6.63 billion. The Next Generation Sequencing (NGS) market is primarily driven by the several advantages of high-performance sequencing over previous genetic technologies, such as microarray and sanger-seq. Additionally, it is predicted that the availability of sample methods with less DNA input will lower total costs, increasing the usage of next-generation sequencing in a variety of academic and medical settings.
Numerous businesses and investors across a wide range of industries, including foundational research, the development and manufacturing of pharmaceutical treatments, and reproductive and consumer genomics, have expressed an interest in this technology. Additionally, the diversification of this technology into other therapeutic sectors is anticipated to benefit from the lowering prices of next-generation data and their additional value relative to traditional data, which supports attractive revenue growth.
The field of genomic research has changed as a result of NGS. A single day can be used to sequence the entire human genome thanks to the ground-breaking NGS technology. NGS provides improved extensibility and fast sequencing, which have beneficial uses for research and development. The methods for preparing samples are changing as a result of developments in sequencing technologies. Correct sequencing and high-quality data are produced as a result of pre-sequencing techniques like target enrichment and library preparation. The market for NGS sample preparation has grown due to the standardization of sample preparation methods brought about by ongoing advancements in the field of NGS sample preparation.
Further key findings from the report suggest
Oncology is regarded as the product with the highest market income share for the next-generation series.
Genetic testing of the GNS will significantly improve health outcomes and death rates, driving acceptance of this market segment.
Targeted sequencing dominated revenue shares in terms of coverage scope and multiplexing capability due to its many advantages across the entire genome market.
In January 2018, Illumina, Inc. and KingMed Diagnostics reached an agreement to collaborate to develop ground-breaking oncology and genetic disease research applications using Illumina’s next-generation sequencing (NOT) technology. The partnership intends to give patients across China precision medications and is a crucial step toward the examination and approval of the Chinese Food and Drugs Authority (CFDA).
Agilent Technologies, Bio-Rad Laboratories, Inc., BGI; Biomatters Ltd., Congenica Ltd., Eurofins Scientific, DNASTAR, F. Hoffmann-La Roche Ltd., Genomatix GmbH, Thermo Fisher Scientific, and Foundation Medicine are a few of the major competitors in the market.
For this report, Emergen Research has segmented the global NGS Sample Preparation Market based on Workflow, Application, End-User, and region:
Workflow Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027)
- NGS Library Preparation Kits
- Semi-automated Library Preparation
- Automated Library Preparation
- Clonal Amplification
Application Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027)
- Clinical Investigation
- Reproductive Health
- HLA Typing/Immune System Monitoring
- Metagenomics, Epidemiology & Drug Development
- Agrigenomics & Forensics
- Consumer Genomics
End-User Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027)
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
Regional Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027)
- North America
- the UK
- the Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Saudi Arabia
- Rest of MEA